Why the study?
Does fixed-dose certoparin reduce thrombus extension and clinical endpoints in adults with acute deep vein thrombosis compared to adjusted-dose intravenous unfractionated heparin?
Population
797 adults with acute deep vein thrombosis (DVT) from a pooled analysis of two clinical trials.
Comparison
Certoparin 8000 antifactor Xa U twice a day vs Adjusted-dose intravenous unfractionated heparin
Design
Meta-analysis, randomized
Follow-up
end of the initial therapy
Authors
Loading...
Supports certoparin over UFH for acute DVT; extends LMWH class benefit in composite outcomes.
Does fixed-dose certoparin reduce thrombus extension and clinical endpoints in adults with acute deep vein thrombosis compared to adjusted-dose intravenous unfractionated heparin?
Fixed-dose certoparin significantly reduces thrombus size and the composite of recurrent VTE, major bleeding, and mortality compared to adjusted-dose UFH during initial DVT treatment.
Harenberg et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: